Dual drug targeting to kill colon cancers
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction: Colorectal cancer (CRC) is driven by a small set of oncogenic and tumour suppressor mutations. However, different combinations of mutations often lead to poor tumour responses to individual anticancer drugs. We have investigated the antiproliferative and in vitro cytotoxic activity of pair‐wise combinations of inhibitors which target specific signalling pathways in colon cancer cells. Objectives: To target specific signaling pathways pairwise with inhibitors in order to kill colon cancer cells. Methods: The effects of different concentrations of two inhibitors on the proliferation and viability of colon cancer cell lines were measured using cell titre glow and cytotoxic assays in 2D and 3D cell micro‐cultures. One successful drug combination was used to treat a colon cancer cell line growing as a xenograft in nude mice. Results: Colon cancer cells in non‐adherent cultures were killed more effectively by combinations of pyrvinium pamoate (a Wnt pathway inhibitor) and ABT263 (a pro‐apoptotic Bcl‐2 family inhibitor) or Ly29004 (a PI3kinase inhibitor). However, in a mouse xenograft model, the formulation and toxicity of the ABT737/PP combination prevent the use of these drugs for treatment of tumours. Fortunately, oral analogues of PP (pyrvinium phosphate, PPh) and ABT737(ABT263) have equivalent activity and can be used for treatment of mice carrying SW620 colorectal cancer xenografts. The PPh/ABT263 induced SW620 tumour cell apoptosis and reduced the rate of SW620 tumour growth. Conclusion: By combining a Wnt signaling inhibitor (pyrvinium phosphate) and a pro‐survival inhibitor (ABT263) colon cancer cells can be killed. Combinations of Wnt signalling inhibitors with an inhibitor of the Bcl pro‐survival protein family should be considered for the treatment of patients with precancerous colon adenomas or advanced colorectal cancers with APC mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When used as monotherapy in three cetuximab-sensitive PDX models, A-1331852 did not substantially affect tumor growth (Supplementary Fig. S5), in line with previous studies in human colorectal cancer cell line xenografts showing negligible single-agent activity of BH3 mimetics against BCL-XL (40, 41).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
Thorne, C. A., Hanson, A. J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C. S., Jernigan, K. K., Meyers, K. C., Hang, B. I., Waterson, A. G., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.453 · Cited by 485
Mouradov, D., Sloggett, C., Jorissen, R. N., Love, C. G., Li, S., Burgess, A. W., Arango, D., Strausberg, R. L., Buchanan, D., Wormald, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0013 · Cited by 375
Self-citationBiomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Esumi, H., Lu, J., Kurashima, Y., & Hanaoka, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03330.x · Cited by 127
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications
Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86
Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
Luo, M.-J., Palmieri, M., Riffkin, C. D., Sakthianandeswaren, A., Djajawi, T. M., Hirokawa, Y., Shuttleworth, V., Segal, D. H., White, C. A., Nhu, D., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02815-0 · Cited by 19
Research works printed but not linked: 47
- 10.14740/gr1239 · DOI · Paper page
- 10.1056/NEJMoa071834 · DOI · Paper page
- 10.1038/s41598-020-76756-1 · DOI
- 10.1038/s41598-019-51981-5 · DOI · Paper page
- 10.3892/ijo.2016.3337 · DOI · Paper page
- 10.1056/NEJMoa1513257 · DOI · Paper page
- 10.1371/journal.pone.0003951 · DOI · Paper page
- 10.1038/nature03579 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-5836 · DOI · Paper page
- Coffey RJ, 1987, Transforming growth factor α and β expression in human colon cancer lines: implications for an autocrine model, Cancer Res, 47, 4590
- Coffey RJ, 1986, Production of transforming growth factors by human colon cancer lines, Cancer Res, 46, 1164
- 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
- 10.1042/BJ20121140 · DOI · Paper page
- 10.1091/mbc.E20-05-0321 · DOI
- 10.1002/ijc.24289 · DOI
- 10.1053/j.gastro.2007.10.008 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-2088 · DOI · Paper page
- 10.1083/jcb.139.4.1017 · DOI · Paper page
- 10.1073/pnas.0809957105 · DOI · Paper page
- 10.3109/08941939.2011.636476 · DOI
- 10.1242/dev.083154 · DOI · Paper page
- 10.3390/molecules25184094 · DOI
- 10.1186/s12943-015-0326-0 · DOI
- 10.1002/pbc.22740 · DOI
- 10.1038/nm.3048 · DOI · Paper page
- 10.1016/j.amjms.2017.11.017 · DOI
- 10.1038/sj.cdd.4401962 · DOI · Paper page
- 10.1038/nm.4010 · DOI · Paper page
- 10.18632/aging.103177 · DOI · Paper page
- Li W, 2020, Wnt/β‐catenin signaling may induce senescence of chondrocytes in osteoarthritis, Exp Ther Med, 20, 2631
- 10.1128/MCB.06023-11 · DOI · Paper page
- 10.1016/j.bbrc.2017.04.110 · DOI
- 10.1016/j.molcel.2007.05.034 · DOI · Paper page
- 10.1038/s41467-018-08150-5 · DOI
- Heinemann V, 2020, FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per‐protocol analysis of FIRE‐3, a randomised clinical trial, Br J Cancer, 124, 1
- 10.21873/anticanres.13146 · DOI
- 10.3390/cancers11070978 · DOI · Paper page
- 10.1038/s41418-019-0391-9 · DOI
- 10.1016/S0021-9258(17)37680-9 · DOI · Paper page
- 10.3390/cancers12041009 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-0362 · DOI
- 10.1158/0008-5472.CAN-19-1184 · DOI
- 10.1016/j.jss.2007.04.021 · DOI · Paper page
- 10.1038/s42003-021-02607-y · DOI
- 10.1111/j.1349-7006.2006.00348.x · DOI
- 10.1158/1078-0432.CCR-12-1740 · DOI · Paper page
- 10.1001/jama.2012.8780 · DOI · Paper page
Cited by
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
Metadata
- Authors
- Corona, S. P., Walker, F., Weinstock, J., Lessene, G., Faux, M., & Burgess, A. W.
- Affiliations
- Structural Biology Division WEHI Parkville Australia
- Department of Medical Biology University of Melbourne Parkville Australia
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2022-03-17
- Volume
- 11
- Issue
- 13
- Pages
- 2612-2626
- ISSN
- 2045-7634
- Cited by
- 8
- References
- 6
- Language
- en
- Funders
- Walter and Eliza Hall Institute
- National Health and Medical Research Council (Development Grant # 1017059, Program Grant # 487922)
- Ludwig Institute for Cancer Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.